Business Wire

Favorable safety profile of Pradaxa® (dabigatran etexilate) confirmed in large prospective real-world analysis

Jaa

New data from one of the largest prospective ongoing global studies examining the use of oral antithrombotics for stroke prevention in atrial fibrillation (AF) in clinical practice, GLORIATM-AF, were presented at the EHRA 2018, the annual congress of the European Heart Rhythm Association (EHRA).1,2 The registry examined two-year safety and effectiveness outcomes of nearly 5,000 AF patients treated with dabigatran (marketed as Pradaxa®). Results of the completed Phase II of GLORIATM-AF,1 presented during the ‘Late-breaking science – Registries’ session, showed low rates of major bleeding (0.97%) and stroke (0.65%). These findings confirm the sustained safety and effectiveness of dabigatran and are highly consistent with the long-term safety profile observed in other real-world evidence, as well as in randomised clinical trials.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180320005661/en/

“Long-term, ‘real-world’ data are important to cardiologists as they help build a bigger picture of how an antithrombotic medication works in daily clinical practice,” commented Gregory Y H Lip, MD, Co-Chair of the GLORIATM-AF Steering Committee. “The results from the second phase of GLORIATM-AF underline the safety and effectiveness of dabigatran, which is reassuring for physicians treating patients with atrial fibrillation.”

In an additional analysis from GLORIATM-AF2 the safety of uninterrupted dabigatran for patients undergoing cardiovascular (CV) interventions was evaluated. The rates of major bleeding and stroke/ systemic embolism were very low, i.e. one major bleed and one systemic embolic event occurred in 412 CV interventions that were performed with uninterrupted dabigatran.

“From the first clinical trials such as RE-LY® and RELY-ABLE®, through to numerous real-world studies, both supported by and independent from Boehringer Ingelheim, we get an absolute, consistent picture of the favorable safety of dabigatran,” commented Professor Jörg Kreuzer, Vice President Medicine, Therapeutic Area Cardiovascular, Boehringer Ingelheim. “Recent clinical trials in specific settings like RE-CIRCUITTM,3 with dabigatran in AF patients undergoing cardio ablation, again demonstrated the superior safety of Pradaxa® compared to standard-of-care. The prospective, long-term data for dabigatran from GLORIATM-AF now add one further piece to complete this picture with profound real-world evidence.”

AF is the most common cardiac rhythm disorder worldwide, with numbers expected to rise in the coming years.4 Overall, people diagnosed with AF have a five-fold increased risk of stroke,5 which occurs when a blood clot blocks a vessel in the brain. Each year three million patients suffer AF-related strokes.6,7

~ENDS~

Please click on the link for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/EHRA-Congress-2018

For more information, please visit:  www.boehringer-ingelheim.com

Further Media Channels

www.facebook.com/boehringeringelheim

www.twitter.com/Boehringer

Contact information

Boehringer Ingelheim GmbH
Corporate Communications
Media + PR
Friederike Middeke, +49 6132 – 77 141575
Fax: +49 6132 – 77 6601
press@boehringer-ingelheim.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

CONQUEST Completes the Financing of Its Sustainable Infrastructure Portfolio24.9.2018 13:18Tiedote

CONQUEST Asset Management (“CONQUEST”) announced it completed, on behalf of the Sustainable Infrastructure fund it manages, the financing of its solar photovoltaic assets portfolio. The transaction was closed with a major financial institution following a competitive selection process. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180924005404/en/ Photo Credit: Istock Prior to this transaction, CONQUEST had increased the size of its assets under management to circa 70MW as a result of 3 transactions closed in less than a year. This portfolio, located in the South of France, benefits from up to 20-year secured and inflation linked power purchase agreements from local incumbent utility EDF. “The financing market remains competitive across Western Europe for sustainable infrastructure. We are pleased with the outcome of this process and the quality of the project finance lenders and teams we managed to attract, which confirmed

L&T Technology Services (LTTS) wins USD 40 million Engineering Content Management (ECM) Deal in Europe24.9.2018 11:20Tiedote

L&T Technology Services Limited (NSE: LTTS), a leading global pure-play engineering services company, today announced that it has won a multi-year deal to provide digital content management services to a leading technology company’s industrial products segment. The deal is expected to run for a period of 5 years with an aggregate revenue potential of USD 40 million, covering Engineering Content Management (ECM) programs in the US and European regions. LTTS will leverage centers in Europe, US & India while assuming complete ownership and talent to manage content for all current and future product suites for the customer. This would include technical design specifications, diagnostic solutions for service engineers and product training for customers & engineers, thereby supporting the entire ECM cycle from product conceptualization to developing digital content platforms. “With engineering content becoming one of the cornerstones of digital transformation, this deal win highlights LTTS’

Prima Solutions Expands Product Offering and Geographical Reach Through the Acquisition of ICOD Inc.24.9.2018 11:00Tiedote

As part of its continuing growth strategy, Prima Solutions (Prima), the premier software platform for Property and Casualty insurers, has agreed to acquire ICOD Inc. (ICOD), the Canadian provider of software solutions for Life and Health insurance. Recognized as an established leader with its SN Assurance suite, ICOD offers a best-in class solution deliverable in SaaS or on premise. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180924005019/en/ The transaction, which closed on September 20th, accelerates Prima’s expansion into the Life and Health insurance market which is still largely using legacy technologies. The ICOD acquisition offers many synergies including: complementing Prima’s existing product offering, diversifying its customer base and expanding the platform for rapid growth in both Europe and North America. Hugues Delannoy, Chairman of Prima Solutions, said: "This acquisition provides a unique opportunity to ac

GE Renewable Energy Launches Cypress Onshore Wind Platform, Designed to Grow, Adapt, Thrive and Lower the Cost of Electricity for Customers24.9.2018 10:00Tiedote

GE Renewable Energy (NYSE:GE) today launched its new onshore turbine platform, named Cypress, and the next model from that platform, GE’s 5.3-158 turbine. The platform advances the proven technology of GE’s 2MW and 3MW fleets, which serves an installed base of nearly 20GW, while also utilizing architecture and innovations from the 4.8-158 turbine introduced in 2017. Cypress enables significant AEP improvements, increased efficiency in serviceability, improved logistics and siting potential, and ultimately more value for customers. It is designed to scale over time, enabling GE to offer a wider array of power ratings and hub heights to meet customer needs throughout the 5MW range. The platform also offers up to a 50 percent increase in AEP over the life of the platform versus GE’s 3MW turbines. It is the second major technology platform launch of the year for GE, which introduced the Haliade-X offshore turbine platform in March. This press release features multimedia. View the full rele

MarketSight Now Available in Six Languages24.9.2018 09:30Tiedote

MarketSight, LLC, a leading provider of data analysis and visualization solutions, has just introduced its award-winning solution in several new languages in its version 11.0 release. Originally available only in English, MarketSight is now being offered in French, German, Italian, Portuguese, and Spanish. MarketSight has always offered support for data in any language. With this new release, it becomes one of the only data analysis and visualization platforms for researchers offered with multiple language options. In addition to making MarketSight accessible to new users whose first language is not English, this new release also gives multilingual teams the ability to collaborate much more efficiently. Market research teams, consulting firms, and other global enterprises working in different languages can work on projects simultaneously while using MarketSight in the language they are most comfortable with. They can also share important findings with international clients through the

Cytox Expands Collaboration with AIBL to Identify Those Most at Risk to Rapidly Progress to Alzheimer’s24.9.2018 08:00Tiedote

Cytox, a precision medicine company which today is commercializing polygenic risk scoring (PRS) approaches for assessing genetic risk for developing Alzheimer’s disease (AD) and other neurological diseases, has announced it has expanded its research collaboration with the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL) to test new algorithms for identifying the pre-symptomatic and mild cognitively impaired people most at risk to progress to AD. Under the expanded agreement Cytox will assess genetic risk for accelerated development of AD using its current, commercially available, research use only approaches developed to run on the Thermo Fisher Scientific Applied Biosystems™ GeneTitan™ Multi-Channel (MC) instrument platform. AIBL will provide biobank samples together with associated longitudinal data from study research participants clinically diagnosed as cognitively normal, with mild cognitive impairment or with AD. Each subject has confirmed amyloid status

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme